Dr. Agarwals Health Care Ltd - 544350 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Dr. Agarwal's Health Care Limited announced NCLT-convened meetings on July 02, 2026, for its equity shareholders, secured creditors, and unsecured creditors. The meetings are to consider and approve a Scheme of Amalgamation between Dr. Agarwal's Eye Hospital Limited and Dr. Agarwal's Health Care Limited. E-voting will be available from June 07 to July 01, 2026.
Jun 01 2026 18:44:03
Dr. Agarwals Health Care Ltd - 544350 - Letter To Equity Shareholders And Creditors
Dr. Agarwal's Health Care will hold NCLT-convened meetings on July 2, 2026, for equity shareholders and creditors. The meetings will consider and approve a Scheme of Amalgamation with Dr. Agarwal's Eye Hospital Limited.
Jun 01 2026 18:08:17
Dr. Agarwals Health Care Ltd - 544350 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Dr. Agarwal's Health Care will convene a meeting of unsecured creditors on July 2, 2026, to approve the scheme of amalgamation with Dr. Agarwal's Eye Hospital. The proposed share exchange ratio is 23 AHCL shares for every 2 AEHL shares, aiming for operational efficiencies and shareholder value.
Jun 01 2026 12:26:26
Dr. Agarwals Health Care Ltd - 544350 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Dr. Agarwal's Health Care has called a meeting of its secured creditors on July 2, 2026, to consider and approve the scheme of amalgamation with Dr. Agarwal's Eye Hospital. This merger is expected to bring operational and financial efficiencies, creating shareholder value.
Jun 01 2026 12:20:35
Dr. Agarwals Health Care Ltd - 544350 - Notice Convening Meeting Of The Equity Shareholders Of The Company Pursuant To The Order Of Hon''ble NCLT, Chennai Bench
Dr. Agarwal's Health Care (AHCL) is convening a meeting on July 2, 2026, to seek shareholder approval for its scheme of amalgamation with Dr. Agarwal's Eye Hospital (AEHL). The scheme proposes a share exchange ratio of 23 AHCL shares for every 2 AEHL shares, aiming for operational efficiencies and shareholder value creation.
Jun 01 2026 12:14:45
Dr. Agarwals Health Care Ltd - 544350 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Dr. Agarwal's Health Care's indirect subsidiary, Orbit Healthcare Services (Mauritius) Limited, invested USD 200,000 in Orbit Health Care ETH PLC, making it an indirect wholly-owned subsidiary in Ethiopia. This strategic move expands the company's global presence in healthcare services.
May 26 2026 20:03:57
Dr. Agarwals Health Care Ltd - 544350 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dr. Agarwal's Health Care received a Show Cause Notice from GST authorities demanding Rs.20.50 crores for alleged discrepancies in FY2023-24 tax returns. The company is evaluating the notice and plans to respond within 30 days, not foreseeing a material impact.
May 21 2026 21:07:31
Dr. Agarwals Health Care Ltd - 544350 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Dr. Agarwal's Health Care announced the audio recording of its Q4 FY26 analyst/earnings conference call, held on May 21, 2026, is now accessible on the company's website. This provides investors with detailed discussions on the audited financial results.
May 21 2026 20:35:54
Dr. Agarwals Health Care Ltd - 544350 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Dr. Agarwal's Health Care announced the Monitoring Agency Report for Q4 FY26, issued by ICRA Limited. The report confirmed that the utilization of IPO proceeds was in line with the objects of the issue, with no deviations observed. This indicates sound governance in fund deployment.
May 15 2026 19:16:31
Dr. Agarwals Health Care Ltd - 544350 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dr. Agarwal's Health Care will host an Earnings/Analyst Conference Call on May 21, 2026, from 06:30 P.M. IST to 07:30 P.M. IST to discuss the Annual Financial Results for Q4 FY26 and the full year ended March 31, 2026. The call will be attended by the CEO, CFO, and Head of Investor Relations.
May 14 2026 15:12:08
Read More